RNF214 silencing attenuates prostate cancer progression and modulates mTOR signaling through CAV1 ubiquitination Authors: Zongqiang Wu, Zhiming Huang, Shangfan Liao Published: 2026 ABSTRACT AbstractBackgroundAlthough both RNF214 and CAV1 are implicated in tumor progression and signaling regulation, the role of the RNF214-CAV1 axis in prostate cancer (PCa) remains unclear. This study aims to explore how RNF214 modulates CAV1 stability via ubiquitination and its influence on PCa progression and mTOR signaling.MethodsThe expression patterns and functional impact of RNF214 were assessed using clinical PCa tissues, cultured cell lines, and mouse xenograft models. Gene silencing experiments were conducted to evaluate effects on cell proliferation, migration, and signaling activity. Protein interactions and ubiquitination were examined via GST pull-down and co-immunoprecipitation. Immunohistochemistry was used to assess proliferation and pathway markers in vivo.ResultsRNF214 expression was elevated in PCa samples, whereas CAV1 was downregulated, with an inverse correlation observed at both transcript and protein levels. RNF214 knockdown inhibited proliferation and migration of PCa cells, accompanied by upregulation of CAV1. A direct interaction between RNF214 and CAV1 was confirmed, and CAV1 ubiquitination was enhanced by RNF214. Dual knockdown of RNF214 and CAV1 restored cell growth and mTOR pathway activity, including phosphorylation of 4EBP1, S6K1, and S6. In xenograft models, tumor suppression induced by RNF214 silencing was reversed by CAV1 co-depletion. Immunohistochemistry showed corresponding changes in Ki67, PTEN, and CAV1 expression.ConclusionRNF214 promotes prostate tumor progression by ubiquitinating and targeting CAV1 for degradation, thereby sustaining mTOR signaling. These findings highlight the RNF214-CAV1 axis as a potential therapeutic target in PCa.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13578-026-01573-4.Keywords: Prostate cancer, RNF214, Caveolin-1, mTOR pathway, Ubiquitination Introduction Prostate cancer (PCa) is the most common malignancy in men and a major cause of cancer-related mortality worldwide [1, 2]. While prostate-specific antigen (PSA) screening and androgen deprivation therapy (ADT) have improved early detection and initial disease control, a significant proportion of patients ultimately progress to castration-resistant PCa [3]. This advanced stage is marked by sustained tumor growth despite hormonal suppression and is frequently associated with metastasis, therapeutic resistance, and poor clinical outcomes [4]. Despite treatment advancements, the specific molecular mechanisms that drive the progression of PCa remain poorly understood. Discovering novel regulators involved in this process is vital for the advancement of targeted therapeutic interventions. Among emerging regulators of cancer signaling, the ubiquitin-proteasome system (UPS) plays a pivotal role in maintaining cellular proteostasis [5]. E3 ubiquitin ligases, as specificity-conferring enzymes in the UPS, orchestrate the targeted ubiquitination and subsequent fate of numerous intracellular proteins [6, 7]. Several E3 ligases-such as MDM2, RNF8, and TRIM25-have been implicated in tumorigenesis through modulation of oncogenes, tumor suppressors, and DNA repair proteins [8–10]. However, many RING-domain E3 ligases remain insufficiently characterized. RING finger protein 214 (RNF214) is one such underexplored ligase, structurally defined by a canonical RING domain and predicted to engage in substrate-directed ubiquitination [11]. Recent findings in hepatocellular carcinoma (HCC) suggest that RNF214 may promote oncogenic activity via non-proteolytic ubiquitination of TEAD transcription factors, thereby modulating the Hippo pathway through a phase separation-dependent mechanism [12]. Nevertheless, whether RNF214 also participates in classical proteolytic ubiquitination-particularly in targeting membrane-associated proteins for degradation-remains unknown. Currently, its expression pattern, biological role, and downstream effectors in PCa have not been elucidated. Caveolin-1 (CAV1), a membrane-anchored scaffolding protein and a defining component of caveolae, exerts complex and context-dependent roles in cancer biology [13]. In early-stage tumors, CAV1 is often silenced and may act as a tumor suppressor [14]. Conversely, its overexpression in advanced PCa has been associated with enhanced proliferation, invasion, resistance to ADT, and poor prognosis [15–18]. Given its multifaceted functions, the regulation of CAV1 expression and stability is critical for cellular homeostasis [19]. The turnover of CAV1 is presumably orchestrated by specific E3 ubiquitin ligases, which facilitate its targeted degradation in a context-dependent fashion [20, 21]. However, the precise E3 ligases responsible for mediating CAV1 degradation through the ubiquitin-proteasome pathway in PCa remain unidentified. Notably, RNF214 has been suggested to play a role in regulating several membrane-associated proteins [11]. Although direct evidence linking RNF214 to CAV1 is currently lacking, this unexplored connection offers a promising opportunity for future research, potentially unveiling a novel mechanism that governs CAV1 stability in PCa. The mTOR pathway is integral to the regulation of cell growth, metabolism, and protein synthesis, positioning it as a crucial factor in cancer biology [22, 23]. Notably, the phosphorylation of 4EBP1, S6K1, and S6 is a well-established marker of mTOR activation, facilitating translation initiation and driving protein synthesis in response to diverse extracellular stimuli [24]. Dysregulation of this pathway is commonly observed in cancer, including PCa, where it plays a pivotal role in promoting cell proliferation, survival, and resistance to therapies [25–27]. CAV1 has been implicated in the regulation of various pathways, including mTOR in various diseases and cellular contexts [28, 29]. For instance, studies suggested that CAV1 regulates mTOR signaling in conditions like non-alcoholic fatty liver disease (NAFLD) and cancer metastasis [29, 30]. However, the specific role of CAV1 in modulating the 4EBP1-S6K1-S6 axis of the mTOR pathway in PCa remains unclear. In this study, we examined RNF214 and CAV1 expression in PCa tissues and cell lines, investigating their interaction in cell proliferation, migration, and the underlying mechanisms through biochemical and molecular assays. We also explored the impact of RNF214-mediated CAV1 regulation on mTOR-4EBP1-S6K1-S6 signaling and validated its in vivo relevance in a mouse xenograft model. Therefore, our findings reveal a novel ubiquitin-dependent pathway by which RNF214 promotes CAV1 degradation, contributing to oncogenic signaling and advancing our understanding of PCa progression. Materials and methods Clinical tissue specimens A total of 40 matched PCa and adjacent non-tumorous tissue samples were obtained from patients who underwent radical prostatectomy at Sanming First Hospital Affiliated to Fujian Medical University. All collected specimens were rapidly snap-frozen in liquid nitrogen and stored at ultra-low temperatures until further use. All research protocols involving human tissues received approval from the Ethics Committee of Sanming First Hospital Affiliated to Fujian Medical University, and informed consent was obtained in writing from each participating individual. Cell culture Human PCa cell lines (PCa3, Du145, LNCaP, C4-2, 22RV1, and VCaP) and normal prostate epithelial cells (RWPE-1) were purchased from Biobw Biotechnology (China), and originally sourced from the ATCC (USA). PCa3, Du145, and RWPE-1 were cultured in RPMI-1640 (Gibco, Cat# 11875093), while the others were maintained in DMEM (Gibco, Cat# 11965092), both supplemented with 10% FBS (Gibco, Cat# 10099141 C) in a 37 °C, 5% CO2 incubator. qRT-PCR Total RNA was extracted from samples using TRIzol reagent (Invitrogen, Cat# 15596026) following standard protocols. cDNA synthesis was performed using the PrimeScript RT Master Mix (Takara, Cat# RR036A). Quantitative PCR was subsequently carried out with TB Green Premix Ex Taq II (Takara, Cat# RR820A) on a CFX96 real-time PCR detection platform (Bio-Rad). Relative gene expression was analyzed using the 2−ΔΔCt approach. Western blot Proteins were extracted from cells and tissues using RIPA buffer (Beyotime, Cat# P0013B) with protease cocktail (Beyotime, Cat# P1045). Protein (40 µg) was resolved by SDS-PAGE and transferred to PVDF membranes (Millipore, Cat# IPVH00010). After blocking with 5% BSA, membranes were incubated with primary antibodies targeting RNF214 (Abcam, ab122227), CAV1 (Abcam, ab2910), p-4EBP1 (Abcam, ab32024), p-S6K1 (Abcam, ab32359), p-S6 (Abcam, ab32529), PTEN (Abcam, ab32199), Ki67 (Abcam, ab15580), and GAPDH (Abcam, ab181602). All primary antibodies were diluted 1:1000. HRP-conjugated secondary antibodies (Abcam, ab6721) were applied at 1:5000 for 1 h. Then blots were developed with ECL substrate (Thermo, Cat# 32106). Lentiviral infection and plasmid transfection sgRNAs targeting RNF214 and shRNAs against CAV1 were cloned into pLKO.1 and pLenti-CMV vectors, respectively (GeneChem, Shanghai, China). Lentivirus was produced in HEK293T cells using packaging plasmids psPAX2 and pMD2. G. Target cells were infected in the presence of 8 µg/mL polybrene (Sigma, Cat# H9268) and selected with puromycin (2 µg/mL; Sigma, Cat# P8833) for 7 days. Transient transfections (e.g., GST-CAV1, EGFP-RNF214) were performed using Lipofectamine 3000 (Invitrogen, Cat# L3000015). CCK-8 The treated cells were plated in 96-well plates (2 × 103 cells/well) and added with CCK-8 (Dojindo, Cat# CK04). The absorbance was measured at 450 nm after 0, 48, and 96 h using a microplate reader (BioTek). Colony formation assay Cells were seeded at 500 cells/well in 6-well plates and cultured for 10–14 days. Colonies were fixed and staine, and the clusters containing over 50 cells were counted under a light microscope. Wound healing assay Cells were seeded into 6-well plates and grown to full confluence. A straight scratch was created across the monolayer using a sterile 200 µL pipette tip. Detached cells were removed by washing with PBS, and fresh serum-free medium was added. Images were acquired at 0 h and 48 h using a phase-contrast microscope. The wound width was quantified with ImageJ software. Transwell assay Cells (5 × 104) suspended in 200 µL serum-free medium were seeded into Transwell chambers (Corning, Cat# 3422), with 10% FBS-containing medium (600 µL) in the lower chamber. After 24 h, migrated cells were fixed, stained with crystal violet (Beyotime, Cat# C0121), and counted using an inverted microscope. GST pull-down assay Recombinant GST and GST-tagged RNF214 fusion proteins were produced in Escherichia coli BL21 (DE3) cells. Expression was induced by adding 0.5 mM IPTG and incubating the cultures for 4 h at 30 °C. Bacterial pellets were collected and lysed in pre-chilled PBS containing protease inhibitors (Beyotime, Cat# P1005). After centrifugation, the clarified lysates were incubated with glutathione-Sepharose 4B beads (GE Healthcare, Cat# 17-0756-01) at 4 °C for 2 h to immobilize GST or GST-RNF214. The beads were washed thoroughly to remove non-specific proteins. His-tagged CAV1 recombinant protein (Abcam, Cat# ab236323) was added to the bead-bound complexes and allowed to interact for another 2 h at 4 °C with gentle rotation. After incubation, beads were washed repeatedly and bound proteins were eluted by boiling in SDS sample buffer. The protein was analyzed by Western blot to detect His-CAV1 binding. Co-immunoprecipitation (Co-IP) Cells were harvested and lysed using IP lysis buffer supplemented with protease inhibitors (Beyotime, Cat# P0013). After brief sonication and centrifugation at 12,000×g for 15 min at 4 °C, the clarified lysates were incubated overnight at 4 °C with either anti-RNF214 (Abcam, Cat# ab122227) or anti-CAV1 (Abcam, Cat# ab2910) antibodies under constant rotation. The next day, protein A/G magnetic beads (Thermo Fisher, Cat# 88803) were added to the mixtures and incubated for an additional 2 h to allow immune complex capture. Beads were then collected and washed thoroughly with cold lysis buffer to eliminate nonspecific binding. Bound proteins were eluted in loading buffer, separated by SDS-PAGE, and examined by Western blot using specific antibodies. Ubiquitination assay To evaluate CAV1 ubiquitination, cells were co-transfected with GST-tagged CAV1 and EGFP-tagged RNF214 plasmids using Lipofectamine 3000 (Invitrogen, Cat# L3000015). After 24 h, transfected cells were harvested and lysed in denaturing lysis buffer containing 1% SDS and protease inhibitors to disrupt non-covalent interactions. Lysates were briefly boiled and diluted with four volumes of PBS to reduce detergent concentration before affinity enrichment. GST-CAV1 was pulled down using glutathione-Sepharose 4B beads (GE Healthcare, Cat# 17-0756-01) at 4 °C for 2 h with gentle rotation. After thorough washing, bound proteins were eluted and resolved by SDS-PAGE. Polyubiquitinated CAV1 was monitored by Western blot with anti-ubiquitin antibody (Abcam, Cat# ab7780). Protein stability assay Cells were treated with 100 µg/mL cycloheximide (Sigma, Cat# C7698) and harvested at 0, 4, 8, and 16 h. CAV1 protein levels were determined by Western blot to evaluate degradation kinetics. Xenograft mouse model Male BALB/c nude mice (4–5 weeks old) were maintained in a pathogen-free facility under the conditions (22 ± 2 °C, 55 ± 10% humidity, 12-hour light/dark cycle) with free access to sterile chow and water. PCa3 cells (5 × 10⁶) stably expressing vector control, sg-RNF214, or sg-RNF214 combined with sh-CAV1 in 100 µL PBS were injected subcutaneously into the right flank. Tumor dimensions were measured every 7 days. On day 28 post-injection, mice were humanely euthanized, and tumors were excised, photographed, and weighed. All animal procedures were approved by the Institutional Animal Care and Use Committee of Sanming First Hospital (Approval No. 2025-92). Immunohistochemistry (IHC) Tumor specimens were fixed, processed routinely, and embedded in paraffin. Sections of 4 μm thickness were prepared using a rotary microtome. Slides were deparaffinized, rehydrated, and subjected to heat-induced antigen retrieval in citrate buffer (pH 6.0). After blocking, sections were incubated overnight at 4 °C with anti-Ki67 (Abcam, Cat# ab15580), anti-PTEN (Abcam, Cat# ab32199), and anti-CAV1 (Abcam, Cat# ab2910), each diluted 1:200 in antibody diluent. After washing and treating with secondary antibodies, they were developed using DAB substrate (Beyotime, Cat# P0203) and counterstained with hematoxylin. Quantification was performed using ImageJ. Statistical analysis All data were derived from three independent experiments and analyzed using SPSS version 22.0. Results are expressed as mean ± SD. Comparisons between two groups were conducted using Student’s t-test, while one-way ANOVA followed by Tukey’s post hoc test was used for multiple group analyses. P < 0.05 was considered statistically significant. Graphs were created with GraphPad Prism 8. Results RNF214 is upregulated while CAV1 is downregulated in PCa tissues, and their expression levels exhibit an inverse correlation To assess the clinical expression profiles of RNF214 and CAV1 in PCa, we analyzed their mRNA levels in 40 paired tumor and adjacent normal tissues using qRT-PCR. As exhibited in Fig. 1A, RNF214 transcript levels were elevated in tumor samples. In contrast, CAV1 expression was notably reduced in PCa tissues (Fig. 1B). To further investigate the potential interplay between the two genes, we conducted a correlation analysis across all tumor samples. As illustrated in Fig. 1C, RNF214 and CAV1 mRNA levels displayed a statistically significant inverse correlation (r² = 0.134, P = 0.02), implying a possible regulatory link between them in the molecular context of PCa. Alterations in CAV1 and RNF214 expression were further examined at the protein level in a cohort of 12 paired PCa and adjacent non-cancerous tissues. As displayed in Fig. 1D, CAV1 protein level was generally decreased in tumor samples, while RNF214 exhibited an elevated pattern compared to matched normal tissues. Quantification of CAV1 level confirmed a significant reduction in cancer tissues (Fig. 1E). Conversely, RNF214 protein expression was found to be increased in most tumor specimens (Fig. 1F). These findings at the protein level are in line with the mRNA trends and imply a potential inverse regulatory relationship between RNF214 and CAV1 in PCa progression. Expression analysis of RNF214 and CAV1 in PCa tissues. A RNF214 mRNA level was monitored by qRT-PCR in 40 pairs of human PCa tissues (T) and adjacent non-tumor tissues (N). B CAV1 mRNA expression was measured by qRT-PCR in the same set of tissue samples. C Correlation between RNF214 and CAV1 mRNA levels in PCa tissues was analyzed using Pearson’s correlation test. D RNF214 and CAV1 protein expressions were examined by Western blot in 12 pairs of PCa tissues (T) and non-cancerous tissues (N). E Quantification of CAV1 expression was performed based on signal intensity analysis. F Relative RNF214 expression was assessed and plotted accordingly. Each data point represents one clinical specimen. *P < 0.05, **P < 0.01, ***P < 0.001 Silencing RNF214 suppresses proliferation and migration of PCa cells Differential expression of RNF214 and CAV1 was observed among various prostate cell lines. As displayed in Fig. 2A, RNF214 protein level was relatively low in RWPE-1 and LNCaP cells, while elevated expression was detected in androgen-independent lines such as Du145 and PCa3. In contrast, CAV1 exhibited a downward trend in these RNF214-high cell lines. Subsequent knockdown of RNF214 was conducted using two independent sgRNA constructs in Du145 and PCa3 cells. As presented in Fig. 2B, RNF214 protein was efficiently reduced by both sg1 and sg2 in each line. Accompanying this reduction, CAV1 expression was consistently increased, indicating a potential suppressive effect of RNF214 on CAV1 in PCa cells. Functionally, CCK-8 assays revealed that silencing RNF214 led to a significant reduction in cell viability in both Du145 and PCa3 cells. As illustrated in Fig. 2C, the growth curves of sg-RNF214-transfected cells displayed a noticeable downward trend over time when compared with vector controls. Consistent with this, the colony formation ability of RNF214-silenced cells was markedly reduced. Fewer and smaller colonies were observed in sg-RNF214 groups relative to controls (vector) (Fig. 2D). In the scratch assay, cell monolayers lacking RNF214 showed delayed wound closure after 48 h (Fig. 2E). Furthermore, Transwell experiments confirmed that fewer cells migrated through the membrane in the sg-RNF214 group, suggesting diminished migration following RNF214 knockdown (Fig. 2F). Effects of RNF214 knockdown on the proliferative and migratory capacities of PCa cells. (A) Western blot analysis of RNF214 and CAV1 levels in RWPE-1 and six PCa cell lines (LNCaP, C4-2, VCaP, Du145, PCa3, and 22RV1). (B) RNF214 was silenced in Du145 and PCa3 cells using two different sgRNA constructs (sg1 and sg2). CAV1 and RNF214 protein levels were examined by Western blot following knockdown. (C) The proliferation of Du145 and PCa3 cells was evaluated by CCK-8 following RNF214 knockdown. (D) Colony formation assays were conducted to assess the long-term proliferative potential of cells transfected with sg-RNF214 or vector control. (E) The changes in migratory ability were identified using Wound healing at 0 h and 48 h post-scratch in Du145 and PCa3 cells. (F) Cell migration was quantified using Transwell assay after RNF214 silencing. **P < 0.01 RNF214 interacts with CAV1 and promotes its ubiquitination and degradation Direct interaction between RNF214 and CAV1 was further demonstrated using purified recombinant proteins. As presented in Fig. 3A, His-tagged CAV1 was pulled down by GST-RNF214, but not by GST alone, confirming a physical binding between the two proteins. This observation was further supported by Co-IP of endogenous proteins in Du145 cells, where RNF214 co-precipitated with CAV1 under native conditions (Fig. 3B). To explore whether this interaction affects CAV1 ubiquitination, we co-expressed EGFP-RNF214 and GST-CAV1 in cells and conducted GST pull-down followed by ubiquitin detection. As shown in Fig. 3C, the ubiquitination signal of CAV1 was markedly increased in the presence of RNF214, but the ubiquitination signal disappeared in the catalytic mutant group (RNF214-C658A). This suggested that RNF214 could enhance CAV1 ubiquitination. Then, the functional impact of RNF214 on CAV1 turnover was evaluated using Protein stability assay. In cycloheximide chase experiments, RNF214 knockdown led to delayed degradation of CAV1 in both Du145 and PCa3 cells (Fig. 3D). These results indicate that RNF214 can promote CAV1 degradation in a time-dependent manner, likely through a ubiquitin-proteasome pathway. Biochemical evidence for the interaction between RNF214 and CAV1, and its effect on CAV1 ubiquitination and stability. (A) Interaction between His-tagged CAV1 and GST-tagged RNF214 was tested using an in vitro GST pull-down approach. The bound proteins were analyzed by Western blot with anti-His antibodies. (B) Endogenous association between RNF214 and CAV1 was examined in Du145 cells via Co-IP. (C) To assess ubiquitination, cells were co-transfected with EGFP-RNF214 or EGFP-RNF214-C658A and GST-CAV1, followed by GST pull-down and Western blot with anti-ubiquitin antibodies. (D) CAV1 protein turnover was tracked in Du145 and PCa3 cells after RNF214 knockdown using a CHX time-course assay. Protein levels at 0 h, 4 h, 8 h, and 16 h were monitored by Western blot, and quantification of protein stability were showed RNF214 modulates the 4EBP1-S6K1-S6 axis via CAV1 in PCa cells To investigate whether the phenotypic effects observed upon RNF214 depletion were mediated by CAV1, co-silencing experiments were conducted in RNF214-deficient Du145 and PC3 cells. As shown in Fig. 4A, RNF214 knockdown markedly elevated CAV1 protein levels, supporting a negative regulatory relationship. Subsequent introduction of shRNA targeting CAV1 in this background effectively reduced CAV1 expression without compromising RNF214 silencing, indicating successful and specific dual-gene modulation. Given the central role of the 4EBP1-S6K1-S6 axis in mTOR signaling, we further evaluated its phosphorylation status following RNF214 knockdown. As illustrated in Fig. 4B, cells with RNF214 depletion (Group II) showed a significant reduction in the phosphorylation of 4EBP1, S6K1 and S6, whereas total protein levels remained largely unchanged. Notably, additional silencing of CAV1 (Group III) partially restored phosphorylation of these downstream targets, a pattern observed consistently across both cell lines. And mRNA expression of 4EBP1, S6K1 and S6 remained unchanged (Supplement Fig. 1). These findings suggest that CAV1 plays a mediating role in the inhibitory effects of RNF214 silencing on the mTOR pathway. RNF214 knockdown suppresses mTOR pathway activity, partially mediated by CAV1. (A) Western blot analysis of RNF214 and CAV1 protein levels in Du145 and PC3 cells transfected with control vector, sg-RNF214, or sg-RNF214 combined with sh-CAV1. (B) Phosphorylated (p-) and total (t-) forms of 4EBP1, S6K1, and S6 were assessed by Western blot to evaluate mTOR signaling activity CAV1 knockdown rescues the proliferation and migration inhibition induced by RNF214 silencing in Du145 and PCa3 cells In CCK-8 assays, cells co-transfected with sg-RNF214 and sh-CAV1 exhibited higher proliferative activity than those with RNF214 knockdown alone (Fig. 5A). A similar trend was observed in colony formation assays (Fig. 5B). In wound healing assays, cells with double knockdown displayed improved wound closure compared to RNF214-silenced cells (Fig. 5C). Transwell migration assays further supported these findings, showing a higher number of migrating cells in the sg-RNF214 + sh-CAV1 group than in the sg-RNF214 group alone (Fig. 5D). Collectively, these results suggest that CAV1 can partly mediate the inhibitory effects of RNF214 knockdown on PCa cell proliferation and migration. We also found similar results in AR-positive cells LNCap (Supplement Fig. 2). CAV1 knockdown reverses the inhibitory effects caused by RNF214 silencing on PCa cell proliferation and migration. Du145 and PC3 cells were treated with vector control, RNF214 knockdown, or combined RNF214 and CAV1 knockdown, followed by a series of functional assays. (A) Cell proliferation was evaluated using CCK-8 at 0 h, 48 h, and 96 h across different groups. (B) Long-term proliferative capacity was assessed by colony formation assays under RNF214 and/or CAV1 silencing conditions. (C) Wound healing assays were conducted at 0 h and 48 h to examine migratory ability. (D) Cell migration was further confirmed using Transwell assay. **P < 0.01 CAV1 knockdown restores the in vivo tumor-suppressive effect of RNF214 knockdown Then, a xenograft tumor model was generated by subcutaneously injecting PCa3 cells transduced with vector, sg-RNF214, or sg-RNF214 plus sh-CAV1 to investigate the contribution of RNF214 and CAV1 to tumor growth in vivo. The data displayed that mice injected with sg-RNF214 cells formed visibly smaller tumors than controls, whereas co-silencing of CAV1 resulted in a partial recovery of tumor size (Fig. 6A). Tumor volume measurements further confirmed that RNF214 knockdown impaired tumor growth, and this suppression was reversed by additional silencing of CAV1 (Fig. 6B). IHC results revealed that RNF214 knockdown resulted in a notable decrease in Ki67 and PTEN expressions, accompanied by elevated levels of CAV1 in tumor tissues. When CAV1 was simultaneously silenced in RNF214-deficient tumors, Ki67 and PTEN staining intensity increased relative to the sg-RNF214 group, while CAV1 expression was effectively reduced (Fig. 6C). These in vivo findings reinforce the functional relevance of the RNF214-CAV1 axis in regulating prostate tumor progression. RNF214 regulates tumor growth in vivo in a CAV1-dependent manner. (A) Representative images of xenograft tumors derived from nude mice injected with PCa3 cells transduced with vector, sg-RNF214, or sg-RNF214 plus sh-CAV1. (B) Tumor volume was monitored every 7 days after cell injection, and growth curves were plotted over a 28-day period. (C) The expressions of Ki67, PTEN, and CAV1 were evaluated with IHC in the three groups Discussion This study presents RNF214 as an E3 ubiquitin ligase involved in the progression of PCa by modulating the stability of CAV1 through ubiquitin-mediated degradation. By integrating molecular, cellular, and in vivo methodologies, we characterized a novel regulatory axis between RNF214, CAV1, and mTOR signaling, providing new insights into the post-translational regulation of oncogenic pathways in PCa. Although RNF214 has been studied in HCC, where it promotes tumor growth through non-degradative ubiquitination of TEAD transcription factors and enhances the transcriptional output of the Hippo pathway [12], its role in PCa remains unclear. In this study, we demonstrated a significant upregulation of RNF214 in both PCa tissues and androgen-independent PCa cell lines, which is accompanied by a consistent decrease in CAV1 expression in tumor samples. These findings diverge from those observed in HCC, where RNF214’s effect is largely attributed to the Hippo pathway modulation. Instead, our data suggested that RNF214 may influence PCa progression through a novel mechanism by regulating the stability of CAV1, an established tumor suppressor. This discovery provides new insight into the role of RNF214 in PCa and suggests its potential as a therapeutic target for this malignancy. CAV1 is a membrane-associated scaffolding protein involved in signaling, endocytosis, and structural membrane domains [31, 32]. Although extensively studied in oncology, its role remains highly dependent on tumor type and biological context [31, 32]. In PCa, secreted CAV1-released via exosomes or autophagy-related pathways-has been reported to promote malignancy by modulating the tumor microenvironment and enhancing angiogenesis and metastasis [16]. Our study focused on the intracellular fraction of CAV1 and uncovered a distinct functional role. RNF214 knockdown resulted in elevated intracellular CAV1 protein levels, accompanied by reduced proliferation and migration in androgen-independent PCa cells. Co-silencing of CAV1 in this context partially restored the malignant phenotype, indicating a functional role for stabilized CAV1. These findings contrast with previous reports emphasizing CAV1’s tumor-promoting effects via extracellular activity [33, 34]. However, similar context-dependent duality has been reported in other cancers. In breast cancer, for example, CAV1 has been implicated in both tumor promotion and suppression, depending on signaling context and molecular subtype [35]. Our data refine this perspective by suggesting that CAV1 may exert tumor-suppressive effects in PCa when its intracellular degradation is impaired, underscoring the importance of RNF214 in this process. Mechanistic assays demonstrated that RNF214 associates with CAV1 and facilitates its ubiquitination, resulting in proteasome-mediated degradation. This provides direct evidence for RNF214’s regulation of CAV1 stability via this mechanism, which contrasts with the traditionally recognized role of CAV1 in enhancing malignancy through its extracellular secretion. CAV1 has been shown to promote tumor malignancy by altering the tumor microenvironment, supporting angiogenesis, and aiding metastasis [34, 36]. However, our findings suggest a distinct function for intracellular CAV1 in PCa, where its stabilization may hinder tumor progression via modulation of the mTOR pathway. The mTOR pathway is pivotal in regulating cell growth, metabolism, and therapeutic resistance in PCa, especially in androgen-refractory cases [37–39]. Although CAV1 has been implicated in modulating mTOR [18, 40], the mechanisms controlling its turnover remain incompletely understood. Our study suggests that RNF214 indirectly influences mTOR signaling through CAV1 degradation, offering new insights into how E3 ligases contribute to oncogenic signaling by regulating protein stability. Our findings also indicate that RNF214 modulates mTOR activity post-translationally, providing a novel understanding of how RNF214 impacts mTOR signaling in cancer. CAV1’s involvement in mTOR regulation appears to be context-dependent, with intracellular CAV1 acting as a tumor suppressor, contrasting with its tumor-promoting roles when secreted into the extracellular space. This duality of CAV1 has been observed in other cancers, such as breast cancer, where CAV1 functions as both a tumor suppressor and a promoter, depending on the specific cellular environment and molecular subtype [34]. In vivo xenograft experiments further confirmed that RNF214 knockdown impaired tumor growth. Importantly, co-silencing of CAV1 partially restored tumor size, indicating that CAV1 plays a significant role in mediating the tumor-suppressive effects of RNF214 knockdown. The partial increase of tumor size upon CAV1 silencing in tumors is consistent with prior studies, which have demonstrated that CAV1 influences PCa growth and metastasis [16, 18]. Besides, CAV1 stabilization in the absence of RNF214 leads to reduced tumor proliferation, as evidenced by Ki67 staining, and an increase in PTEN, a known inhibitor of mTOR signaling. These in vivo findings further confirm the pivotal role of CAV1 in PCa progression, suggesting that RNF214 modulates CAV1 stability to influence tumor growth. In summary, RNF214 emerges as a promising therapeutic target for modulating mTOR activity, particularly in resistant PCa. Given the central role of mTOR signaling in tumorigenesis and treatment resistance, targeting RNF214 could offer a novel approach to overcoming resistance in PCa treatment. Further studies, particularly using patient-derived models, will be essential to evaluate the clinical potential of RNF214 inhibition as a therapeutic strategy for PCa. Despite these insights, several limitations should be considered. Most of our analyses were conducted using established cell lines and xenograft models, which may not fully capture the heterogeneity of clinical disease. Moreover, although our study focused on CAV1 as a primary substrate, RNF214 may target additional proteins involved in tumor progression. We also did not explore whether CAV1 affects pathways beyond mTOR, or how its intracellular and extracellular functions may intersect. Finally, while RNF214 could represent a potential therapeutic target, the feasibility of pharmacologic intervention remains unclear in the absence of selective inhibitors. Further work using patient-derived models and proteome-wide analyses will be necessary to expand on these observations. In summary, this study suggests that RNF214 contributes to PCa cell behavior by promoting CAV1 degradation and altering mTOR pathway. These results support a mechanistic connection between RNF214 activity and intracellular signaling regulation, and provide a foundation for further investigation into ubiquitin-related pathways in PCa progression. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Acknowledgements Not applicable. Funding No funding was received for this manuscript. Data availability The datasets used or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the animal ethics committee of the Sanming First Hospital Affiliated to Fujian Medical University with approval number 2025-92. Consent for publication Not applicable. Conflict of interest The authors declare no conflict of interest. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Data Availability Statement The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.